MX386832B - Inhibidor angptl8 e inhibidor angptl3 para usarse en el tratamiento de hiperlipidemia. - Google Patents
Inhibidor angptl8 e inhibidor angptl3 para usarse en el tratamiento de hiperlipidemia.Info
- Publication number
- MX386832B MX386832B MX2018012221A MX2018012221A MX386832B MX 386832 B MX386832 B MX 386832B MX 2018012221 A MX2018012221 A MX 2018012221A MX 2018012221 A MX2018012221 A MX 2018012221A MX 386832 B MX386832 B MX 386832B
- Authority
- MX
- Mexico
- Prior art keywords
- antibody
- hyperlipidemia
- angptl8
- angptl3
- inhibitor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662319980P | 2016-04-08 | 2016-04-08 | |
| US201762453110P | 2017-02-01 | 2017-02-01 | |
| PCT/US2017/026679 WO2017177181A1 (en) | 2016-04-08 | 2017-04-07 | Methods for treating hyperlipidemia with an angptl8 inhibitor and an angptl3 inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018012221A MX2018012221A (es) | 2019-02-13 |
| MX386832B true MX386832B (es) | 2025-03-19 |
Family
ID=58610026
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018012221A MX386832B (es) | 2016-04-08 | 2017-04-07 | Inhibidor angptl8 e inhibidor angptl3 para usarse en el tratamiento de hiperlipidemia. |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US20170291937A1 (https=) |
| EP (1) | EP3439689B1 (https=) |
| JP (1) | JP6964090B2 (https=) |
| KR (1) | KR20180132843A (https=) |
| CN (1) | CN109789194B (https=) |
| AU (1) | AU2017248356A1 (https=) |
| CA (1) | CA3020175A1 (https=) |
| CY (1) | CY1124902T1 (https=) |
| ES (1) | ES2896107T3 (https=) |
| HR (1) | HRP20212028T1 (https=) |
| HU (1) | HUE056878T2 (https=) |
| IL (1) | IL262130A (https=) |
| LT (1) | LT3439689T (https=) |
| MD (1) | MD3439689T2 (https=) |
| MX (1) | MX386832B (https=) |
| PL (1) | PL3439689T3 (https=) |
| PT (1) | PT3439689T (https=) |
| RS (1) | RS62769B1 (https=) |
| SI (1) | SI3439689T1 (https=) |
| SM (1) | SMT202200016T1 (https=) |
| WO (1) | WO2017177181A1 (https=) |
| ZA (1) | ZA201806264B (https=) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR087329A1 (es) | 2011-06-17 | 2014-03-19 | Regeneron Pharma | Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana |
| TW201713690A (zh) | 2015-08-07 | 2017-04-16 | 再生元醫藥公司 | 抗ａｎｇｐｔｌ８抗體及其用途 |
| JP7541810B2 (ja) | 2016-03-03 | 2024-08-29 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ａｎｇｐｔｌ３阻害剤と組み合わせてｐｃｓｋ９阻害剤を投与することにより高脂血症を有する患者を処置するための方法 |
| IL293308B2 (en) * | 2016-04-28 | 2024-12-01 | Regeneron Pharma | Methods for treating patients with familial hypercholesterolemia |
| WO2018094112A1 (en) * | 2016-11-17 | 2018-05-24 | Regeneron Pharmaceuticals, Inc. | Methods of treating obesity with anti-angptl8 antibodies |
| CA3080148A1 (en) * | 2017-11-10 | 2019-05-16 | Ngm Biopharmaceuticals, Inc. | Angptl8-binding agents and methods of use thereof |
| US11977081B2 (en) | 2017-12-18 | 2024-05-07 | Regeneron Pharmaceuticals, Inc. | ANGPTL8 assay and uses thereof |
| EP3884051A2 (en) * | 2018-11-23 | 2021-09-29 | Sanofi | Novel rna compositions and methods for inhibiting angptl8 |
| TWI747098B (zh) * | 2018-12-21 | 2021-11-21 | 美商美國禮來大藥廠 | 抗angptl3/8複合物抗體及其使用方法 |
| US12559551B2 (en) | 2019-05-24 | 2026-02-24 | Regeneron Pharmaceuticals, Inc. | Stabilized formulations containing anti-ANGPTL3 antibodies |
| CN112062845B (zh) * | 2019-06-10 | 2022-09-02 | 山东博安生物技术股份有限公司 | Angptl3结合片段及其用途 |
| CN110596399B (zh) * | 2019-08-29 | 2022-07-22 | 首都医科大学附属北京安贞医院 | 检测血管生成素样蛋白8含量的物质的应用 |
| CN110613847B (zh) * | 2019-10-23 | 2022-02-11 | 北京市心肺血管疾病研究所 | 一种抑制血管生成素样蛋白8的物质的应用 |
| CN110694068A (zh) * | 2019-11-06 | 2020-01-17 | 北京市心肺血管疾病研究所 | 一种抑制血管生成素样蛋白8的物质的应用 |
| CN110694067A (zh) * | 2019-11-06 | 2020-01-17 | 首都医科大学附属北京安贞医院 | 一种抑制血管生成素样蛋白8的物质的应用 |
| CN110938144B (zh) * | 2019-11-27 | 2022-07-26 | 复旦大学附属儿科医院 | 一种抗angptl3单克隆抗体及其在制备治疗肾病综合征药物中的用途 |
| CN111135303A (zh) * | 2020-01-17 | 2020-05-12 | 北京市心肺血管疾病研究所 | 一种抑制血管生成素样蛋白8的物质的应用 |
| KR20220131935A (ko) * | 2020-01-22 | 2022-09-29 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | 항angptl3 항체 및 이의 용도 |
| AU2021320417A1 (en) * | 2020-08-07 | 2023-03-30 | Regeneron Pharmaceuticals, Inc. | Methods for treating refractory hypercholesterolemia involving an ANGPTL3 inhibitor |
| IL313191A (en) * | 2021-12-22 | 2024-07-01 | Regeneron Pharma | Treatment of kidney diseases using angiopoietin-like inhibitors 3 |
| CN114671943B (zh) * | 2022-04-29 | 2023-05-05 | 四川大学 | 一种鱼类摄食调控蛋白的制备和应用 |
| JP2025521114A (ja) * | 2022-05-16 | 2025-07-08 | シティ・オブ・ホープ | 抗ｃｄ８４抗体及びその使用 |
| CN115947779B (zh) * | 2022-08-10 | 2025-04-25 | 武汉安砥生物科技有限公司 | 针对人血管生成素样蛋白3的免疫原性肽段及其载体疫苗和用途 |
| WO2024130165A1 (en) * | 2022-12-16 | 2024-06-20 | Regeneron Pharmaceuticals, Inc. | Angptl3 inhibitors for triglyceride reduction in multifactorial chylomicronemia syndrome |
| WO2024227059A2 (en) * | 2023-04-27 | 2024-10-31 | Aligos Therapeutics, Inc. | Short interfering nucleic acid (sina) molecules targeting angptl 3 and angptl 8 and methods of using the same |
| CN117535353A (zh) * | 2023-10-11 | 2024-02-09 | 首都医科大学附属北京潞河医院 | 一种糖尿病视网膜病变模型的建立方法及应用 |
| CN119039435A (zh) * | 2024-09-21 | 2024-11-29 | 复旦大学附属儿科医院 | 一种抗angptl3人源化单抗及其应用 |
| CN119367545B (zh) * | 2025-01-02 | 2025-04-08 | 山东第一医科大学(山东省医学科学院) | 靶向干预ANGPTL8 mRNA在制备治疗高同型半胱氨酸血症药物中的应用 |
| CN119971041A (zh) * | 2025-02-05 | 2025-05-13 | 武汉大学 | 特异性降低胆固醇水平但不干扰甘油三酯代谢的分子靶点及其应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| ES2398076T3 (es) | 2006-06-02 | 2013-03-13 | Regeneron Pharmaceuticals, Inc. | Anticuerpos de alta afinidad contra el receptor de IL-6 humano |
| WO2012168491A1 (en) | 2011-06-10 | 2012-12-13 | Novartis Ag | Pharmaceutical formulations of pcsk9 antagonists |
| AR087329A1 (es) * | 2011-06-17 | 2014-03-19 | Regeneron Pharma | Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana |
| AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| EA039663B1 (ru) | 2012-05-03 | 2022-02-24 | Амген Инк. | Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств |
| EP3822287A1 (en) * | 2014-10-03 | 2021-05-19 | NGM Biopharmaceuticals, Inc. | Angptl8 polypeptide and its use for treatment of conditions associated with elevated triglycerides |
| TW201713690A (zh) * | 2015-08-07 | 2017-04-16 | 再生元醫藥公司 | 抗ａｎｇｐｔｌ８抗體及其用途 |
-
2017
- 2017-04-07 KR KR1020187032369A patent/KR20180132843A/ko not_active Abandoned
- 2017-04-07 SI SI201730953T patent/SI3439689T1/sl unknown
- 2017-04-07 WO PCT/US2017/026679 patent/WO2017177181A1/en not_active Ceased
- 2017-04-07 US US15/482,499 patent/US20170291937A1/en not_active Abandoned
- 2017-04-07 CN CN201780035121.1A patent/CN109789194B/zh not_active Expired - Fee Related
- 2017-04-07 HU HUE17719107A patent/HUE056878T2/hu unknown
- 2017-04-07 CA CA3020175A patent/CA3020175A1/en active Pending
- 2017-04-07 EP EP17719107.9A patent/EP3439689B1/en active Active
- 2017-04-07 HR HRP20212028TT patent/HRP20212028T1/hr unknown
- 2017-04-07 AU AU2017248356A patent/AU2017248356A1/en not_active Abandoned
- 2017-04-07 MD MDE20190190T patent/MD3439689T2/ro not_active IP Right Cessation
- 2017-04-07 PT PT177191079T patent/PT3439689T/pt unknown
- 2017-04-07 MX MX2018012221A patent/MX386832B/es unknown
- 2017-04-07 PL PL17719107T patent/PL3439689T3/pl unknown
- 2017-04-07 JP JP2018552824A patent/JP6964090B2/ja active Active
- 2017-04-07 ES ES17719107T patent/ES2896107T3/es active Active
- 2017-04-07 SM SM20220016T patent/SMT202200016T1/it unknown
- 2017-04-07 RS RS20211568A patent/RS62769B1/sr unknown
- 2017-04-07 LT LTEPPCT/US2017/026679T patent/LT3439689T/lt unknown
-
2018
- 2018-09-18 ZA ZA2018/06264A patent/ZA201806264B/en unknown
- 2018-10-04 IL IL262130A patent/IL262130A/en unknown
-
2019
- 2019-11-15 US US16/685,876 patent/US20200377583A1/en not_active Abandoned
-
2022
- 2022-01-07 US US17/571,286 patent/US20220127348A1/en not_active Abandoned
- 2022-01-10 CY CY20221100023T patent/CY1124902T1/el unknown
-
2024
- 2024-08-12 US US18/801,099 patent/US20250066463A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN109789194A (zh) | 2019-05-21 |
| RS62769B1 (sr) | 2022-01-31 |
| ZA201806264B (en) | 2019-07-31 |
| LT3439689T (lt) | 2021-11-10 |
| HRP20212028T1 (hr) | 2022-04-01 |
| US20220127348A1 (en) | 2022-04-28 |
| EP3439689B1 (en) | 2021-10-13 |
| US20170291937A1 (en) | 2017-10-12 |
| MD3439689T2 (ro) | 2021-12-31 |
| HUE056878T2 (hu) | 2022-03-28 |
| CA3020175A1 (en) | 2017-10-12 |
| AU2017248356A1 (en) | 2018-10-25 |
| US20250066463A1 (en) | 2025-02-27 |
| JP6964090B2 (ja) | 2021-11-10 |
| US20200377583A1 (en) | 2020-12-03 |
| IL262130A (en) | 2018-11-29 |
| SI3439689T1 (sl) | 2021-12-31 |
| PL3439689T3 (pl) | 2022-01-31 |
| JP2019513751A (ja) | 2019-05-30 |
| SMT202200016T1 (it) | 2022-03-21 |
| MX2018012221A (es) | 2019-02-13 |
| EP3439689A1 (en) | 2019-02-13 |
| ES2896107T3 (es) | 2022-02-23 |
| PT3439689T (pt) | 2021-11-04 |
| CN109789194B (zh) | 2022-08-02 |
| KR20180132843A (ko) | 2018-12-12 |
| WO2017177181A1 (en) | 2017-10-12 |
| CY1124902T1 (el) | 2023-01-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX386832B (es) | Inhibidor angptl8 e inhibidor angptl3 para usarse en el tratamiento de hiperlipidemia. | |
| MA44764B1 (fr) | Méthodes de traitement de patients présentant une hypercholestérolémie familiale | |
| MX2018010401A (es) | Metodos para el tratamiento de pacientes con hiperlipidemia administrando un inhibidor de pcsk9 en combinacion con un inhibidor de angptl3. | |
| EA201691847A1 (ru) | Способы снижения сердечно-сосудистого риска | |
| BR112017008093A2 (pt) | processos para tratamento de doenças oculares | |
| EA202090510A1 (ru) | Способ лечения бокового амиотрофического склероза придопидином | |
| MA40240A (fr) | Composés hétéroaryle d'inhibition de la kinase | |
| EA202090955A1 (ru) | Способы применения ингибиторов ehmt2 в лечении или предупреждении нарушений со стороны крови | |
| PH12017500493A1 (en) | Combination therapy | |
| MX2017010982A (es) | Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer. | |
| EA201890891A1 (ru) | Биомаркеры, связанные с заболеваниями, опосредованными интерлейкином-33 (ил-33), и их применение | |
| EA201590655A8 (ru) | Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений | |
| WO2018022668A3 (en) | NEUROMODULATORY COMPOSITIONS AND ASSOCIATED METHODS OF TREATING CANCER | |
| BR112018014222A2 (pt) | método de tratamento da glomerulopatia c3 | |
| UY34137A (es) | ANTICUERPOS HUMANOS PARA LA PROTEINA 3 DE TIPO ANGIOPOYETINA HUMANA (hANGPTL3) | |
| EA202192122A1 (ru) | Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения | |
| EA201590654A1 (ru) | Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона | |
| EA201891853A1 (ru) | Способы лечения или предотвращения атеросклероза путем введения ингибитора angptl3 | |
| MX2017016134A (es) | Aril dihidro-2h-benzo[b][1,4]oxazina sulfonamida y compuestos relacionados para uso como agonistas de rory y el tratamiento de enfermedad. | |
| MX2025001920A (es) | Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina | |
| MX2017006938A (es) | Terapia de combinacion para el tratamiento de cancer. | |
| EP4285993A3 (en) | Growth differentiation factor 15 as biomarker for metformin | |
| NZ754676A (en) | Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta | |
| EA201691656A2 (ru) | Терапевтические способы с применением норибогаина и родственных соединений | |
| SG11202104321PA (en) | Combination therapy for treatment of hematological diseases |